about
The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disordersAnthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disordersImproved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies.Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma.Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis.Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer.Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells.Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy.A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting.IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas.Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study.Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer.Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial.Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.Remodeling of the epitope repertoire of a candidate idiotype vaccine by targeting to lysosomal degradation in dendritic cellsLymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIV-infected patientClinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical TrialPredictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area
P50
Q34166602-80ADF91E-BB19-4D6E-8BBB-78CB3A728CBCQ34996054-4BB4308F-26B0-4A62-94D9-72A53E228DFCQ35738744-CF7BDAF7-D043-4075-B477-5D6FA0EF8244Q35789363-63993149-558B-47A5-B6E7-F81D2B1A67E0Q35889604-B85B27CF-6036-4924-9689-7104E3E05979Q36001708-0BE73B8E-9FB4-4333-8C5D-4F3713F9B927Q36306025-B5B1C3D8-0A8C-4B86-B85E-C9ACEDEBBD8DQ37457684-2495FD9B-8294-47ED-ACA9-8BCF183420B6Q37505384-E89C2EE1-B5C1-470C-BBA1-8E5D0253181AQ37667998-4CEC6BC1-D564-4F1D-8BED-6455555BBAF2Q38783775-A1BFB975-9700-45FF-AB01-6E280E3194A2Q38907078-3A239B3B-BCB1-46CC-AFA2-C81416B2D39FQ39329992-09DAA634-99CF-4025-B56D-E6B811C3F389Q41034587-5C680DA1-8F65-4303-9DA1-196897831907Q47115510-FF1CC895-A72E-4B34-A7BB-9BBACBA64EA3Q47931888-57920ACF-A7BE-48F1-8285-DD196DA3B6E0Q50566797-9AC672EC-10D7-415C-9895-6FB48F0883F1Q57056029-D3480452-AFA7-4AD2-AD7B-99B3682E31FFQ59351755-8FD0D725-2281-4958-9C90-D51F50B084DFQ92570753-D5928289-6164-4197-912D-D9C635B704F8Q96617467-3B3D759A-AAC1-4143-9CB9-38FC2A45F730
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Elena Muraro
@en
Elena Muraro
@nl
type
label
Elena Muraro
@en
Elena Muraro
@nl
prefLabel
Elena Muraro
@en
Elena Muraro
@nl
P31
P496
0000-0001-9514-8224